AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,846,438 | +2080.0% | 168,528 | +1722.5% | 0.02% | +1500.0% |
| Q4 2023 | $130,568 | -31.8% | 9,247 | -50.2% | 0.00% | 0.0% |
| Q3 2023 | $191,426 | -88.9% | 18,585 | -82.2% | 0.00% | -90.9% |
| Q2 2023 | $1,724,039 | +281.6% | 104,614 | +112.1% | 0.01% | +266.7% |
| Q1 2023 | $451,817 | -59.9% | 49,325 | -68.6% | 0.00% | -57.1% |
| Q4 2022 | $1,125,624 | +332.9% | 157,210 | +203.4% | 0.01% | +600.0% |
| Q3 2022 | $260,000 | -22.2% | 51,809 | +25.2% | 0.00% | -66.7% |
| Q4 2021 | $334,000 | +89.8% | 41,370 | +130.2% | 0.00% | +50.0% |
| Q3 2021 | $176,000 | -49.3% | 17,973 | -73.9% | 0.00% | -60.0% |
| Q3 2020 | $347,000 | +184.4% | 68,820 | +349.0% | 0.01% | +66.7% |
| Q1 2020 | $122,000 | +84.8% | 15,326 | +41.6% | 0.00% | 0.0% |
| Q2 2018 | $66,000 | -26.7% | 10,820 | -1.5% | 0.00% | -40.0% |
| Q4 2017 | $90,000 | -51.1% | 10,982 | -37.4% | 0.01% | -50.0% |
| Q3 2017 | $184,000 | – | 17,531 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,673,718 | $20,949,000 | 10.15% |
| Vivo Capital, LLC | 3,575,424 | $28,389,000 | 2.57% |
| COWEN AND COMPANY, LLC | 1,517,296 | $10,767,000 | 2.47% |
| VR Adviser, LLC | 1,057,827 | $8,399,000 | 2.28% |
| RTW INVESTMENTS, LP | 4,616,570 | $36,253,000 | 1.56% |
| GENDELL JEFFREY L | 553,516 | $4,395,000 | 1.35% |
| Avoro Capital Advisors LLC | 4,365,655 | $34,663,000 | 1.17% |
| Arlington Capital Management, Inc. | 115,902 | $920,000 | 0.85% |
| Ghost Tree Capital, LLC | 350,000 | $2,779,000 | 0.74% |
| PURA VIDA INVESTMENTS, LLC | 496,660 | $3,943,000 | 0.47% |